6-(2-甲氧基苯甲酰氨基)己酸 | 78121-44-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-(2-甲氧基苯甲酰氨基)己酸
• 英文名称: 6-[(2-methoxybenzoyl)amino]hexanoic Acid
• CAS: 78121-44-5
• 化学式: C₁₄H₁₉NO₄
• mdl: MFCD00426127
• 分子量: 265.309
• InChiKey: IJNYNPWYAVCHLM-UHFFFAOYSA-N

物化性质

• 沸点：
  488.9±30.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(2-甲氧基苯甲酰氨基)己酸 在 lithium aluminium tetrahydride 、 氯甲酸乙酯 、 三乙胺 作用下， 以 二乙二醇二甲醚 为溶剂， 生成 methoctramine
  参考文献：
  名称：

  四胺的合成和选择性 M-胆碱阻断活性。第二部分

  摘要：

  已证明这些物质对胆碱受体 [I] 的 M2 亚型具有选择性亲和力，并且已确定至少一种合成化合物 [XIII: Ar=Ph, A=(CH2)6, B = 1, 4-C6H4(CH2)2] 与甲胺丁胺 [At = 2-MeOC6H4, A = (CH2)6, B = (CHE)s] 相比具有更高的选择性，被认为是该类型中最有前途的制剂 [2] . 这项工作的目的是获得新的四胺 I，其中基团 B 的部分亚甲基被氧原子取代。预计这种取代将显着改变初始化合物的性质。分子极性和亲水性的增加必须改变它们的构象特性，从而改变化合物的生物活性（包括对某些亚型 M-胆碱受体的特异性）。

  DOI：

  10.1007/bf02464370
• 作为产物：
  描述：

  6-氨基己酸 在 sodium carbonate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 6-(2-甲氧基苯甲酰氨基)己酸
  参考文献：
  名称：

  Studies Directed at the Use of a Parallel Synthesis Matrix to Increase Throughput in an in Vivo Assay

  摘要：

  Heparin is the anticoagulant of choice for hospitalized patients, but it is dosed only by injection because it is not absorbed following oral administration. We have discovered and prepared compounds (delivery agents) that facilitate the gastrointestinal absorption of heparin in rats, monkeys, and humans when given orally. We are currently developing a parallel synthesis approach to increase our delivery agent screening throughput in vivo. This approach has been used to produce micromolar quantities of compounds for testing in rats in a 5 x 5 parallel synthesis array. Using an amine benzoylation reaction sequence, 10 mixtures were prepared. These mixtures contained equal weight quantities of five N-substituted, non-alpha, amino acid delivery agents. Each of these mixtures was orally administered to rats in combination with heparin, and plasma clotting times (APTT) were measured to determine activity. Deconvolution of the data accurately identified the most active individual components. Independent synthesis of these compounds verified their activity. This parallel synthesis approach is an effective tool for the screening of oral heparin delivery agents and has increased screening throughput significantly.

  DOI：

  10.1021/jm990416r

文献信息

• COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
  申请人：Sarubbi Donald J.

  公开号：US20090324540A1

  公开（公告）日：2009-12-31

  Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

  本发明提供了用于传递活性剂的载体化合物和组合物。同时还提供了其治疗方法和制备方法。
• Synthesis and Evaluation of Compounds That Facilitate the Gastrointestinal Absorption of Heparin
  作者：Andrea Leone-Bay、Duncan R. Paton、John Freeman、Christine Lercara、Doris O'Toole、David Gschneidner、Eric Wang、Elizabeth Harris、Connie Rosado、Theresa Rivera、Aldonna DeVincent、Monica Tai、Frank Mercogliano、Rajesh Agarwal、Harry Leipold、Robert A. Baughman

  DOI：10.1021/jm970811m

  日期：1998.3.1

  A family of novel compounds (delivery agents) that promote the gastrointestinal absorption of USP heparin in rats and primates has been discovered. The delivery agents in combination with heparin were administered either orally or intracolonically in an aqueous propylene glycol solution and caused dramatic increases in both plasma heparin concentrations (anti-Factor Xa) and clotting times (APTT). Using one of the most effective delivery agents in this series, an estimated relative bioavailability of 8% can be achieved following oral administration to cynomolgus monkeys. To establish a correlation between the in vivo data and an in vitro parameter, immobilized artificial membrane (IAM) chromatography was performed. Log relative k' values were correlated to the efficiency of oral heparin delivery.
• PRASHKYAVICHYUS A.; DUDENAS G.; STANKYAVICHYUS A.; VIZAS V.; PACTEHEHE D.+, LIETTSR AUKSTUJU MOKUKLU MOKSIO DARVAI, MEDISINA, NAUCH. TR. VUZOV LITSSR+
  作者：PRASHKYAVICHYUS A.、 DUDENAS G.、 STANKYAVICHYUS A.、 VIZAS V.、 PACTEHEHE D.+

  DOI：——

  日期：——
• US7553872B2
  申请人：——

  公开号：US7553872B2

  公开（公告）日：2009-06-30
• Studies Directed at the Use of a Parallel Synthesis Matrix to Increase Throughput in an in Vivo Assay
  作者：Andrea Leone-Bay、John Freeman、Doris O'Toole、Connie Rosado-Gray、Sirpa Salo-Kostmayer、Monica Tai、Frank Mercogliano、Robert A. Baughman

  DOI：10.1021/jm990416r

  日期：2000.9.1

  Heparin is the anticoagulant of choice for hospitalized patients, but it is dosed only by injection because it is not absorbed following oral administration. We have discovered and prepared compounds (delivery agents) that facilitate the gastrointestinal absorption of heparin in rats, monkeys, and humans when given orally. We are currently developing a parallel synthesis approach to increase our delivery agent screening throughput in vivo. This approach has been used to produce micromolar quantities of compounds for testing in rats in a 5 x 5 parallel synthesis array. Using an amine benzoylation reaction sequence, 10 mixtures were prepared. These mixtures contained equal weight quantities of five N-substituted, non-alpha, amino acid delivery agents. Each of these mixtures was orally administered to rats in combination with heparin, and plasma clotting times (APTT) were measured to determine activity. Deconvolution of the data accurately identified the most active individual components. Independent synthesis of these compounds verified their activity. This parallel synthesis approach is an effective tool for the screening of oral heparin delivery agents and has increased screening throughput significantly.